Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer

Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and vasculature-governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer research (Chicago, Ill.) Ročník 73; číslo 15; s. 4674
Hlavní autoři:	Nobis, Max, McGhee, Ewan J, Morton, Jennifer P, Schwarz, Juliane P, Karim, Saadia A, Quinn, Jean, Edward, Mike, Campbell, Andrew D, McGarry, Lynn C, Evans, T R Jeffry, Brunton, Valerie G, Frame, Margaret C, Carragher, Neil O, Wang, Yingxiao, Sansom, Owen J, Timpson, Paul, Anderson, Kurt I
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.08.2013
Témata:	Animals Antineoplastic Agents - pharmacology Biosensing Techniques - methods Cells, Cultured Dasatinib Disease Models, Animal Fluorescence Resonance Energy Transfer - methods Imaging, Three-Dimensional - methods Mice Mice, Transgenic Microscopy, Fluorescence Pancreatic Neoplasms - metabolism Pyrimidines - pharmacology src-Family Kinases - metabolism Thiazoles - pharmacology
ISSN:	1538-7445, 1538-7445
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and vasculature-governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to the anti-invasive Src inhibitor dasatinib. A fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse model of pancreatic cancer. In contrast to conventional techniques, FLIM-FRET analysis allowed for accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors. In 3D organotypic cultures, we showed that a spatially distinct gradient of Src activity exists within invading tumor cells, governed by the depth of penetration into complex matrices. In parallel, this gradient was also found to exist within live tumors, where Src activity is enhanced at the invasive border relative to the tumor cortex. Upon treatment with dasatinib, we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo. Src regulation was governed by the proximity of cells to the host vasculature, as cells distal to the vasculature were regulated differentially in response to drug treatment compared with cells proximal to the vasculature. Overall, our results in live tumors revealed that a threshold of drug penetrance exists in vivo and that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenvironments. We propose that using FLIM-FRET in this capacity could provide a useful preclinical tool in animal models before clinical translation.
AbstractList	Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and vasculature-governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to the anti-invasive Src inhibitor dasatinib. A fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse model of pancreatic cancer. In contrast to conventional techniques, FLIM-FRET analysis allowed for accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors. In 3D organotypic cultures, we showed that a spatially distinct gradient of Src activity exists within invading tumor cells, governed by the depth of penetration into complex matrices. In parallel, this gradient was also found to exist within live tumors, where Src activity is enhanced at the invasive border relative to the tumor cortex. Upon treatment with dasatinib, we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo. Src regulation was governed by the proximity of cells to the host vasculature, as cells distal to the vasculature were regulated differentially in response to drug treatment compared with cells proximal to the vasculature. Overall, our results in live tumors revealed that a threshold of drug penetrance exists in vivo and that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenvironments. We propose that using FLIM-FRET in this capacity could provide a useful preclinical tool in animal models before clinical translation.Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and vasculature-governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to the anti-invasive Src inhibitor dasatinib. A fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse model of pancreatic cancer. In contrast to conventional techniques, FLIM-FRET analysis allowed for accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors. In 3D organotypic cultures, we showed that a spatially distinct gradient of Src activity exists within invading tumor cells, governed by the depth of penetration into complex matrices. In parallel, this gradient was also found to exist within live tumors, where Src activity is enhanced at the invasive border relative to the tumor cortex. Upon treatment with dasatinib, we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo. Src regulation was governed by the proximity of cells to the host vasculature, as cells distal to the vasculature were regulated differentially in response to drug treatment compared with cells proximal to the vasculature. Overall, our results in live tumors revealed that a threshold of drug penetrance exists in vivo and that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenvironments. We propose that using FLIM-FRET in this capacity could provide a useful preclinical tool in animal models before clinical translation. Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and vasculature-governing behavior. In this study, we used a novel intravital method that revealed spatiotemporal regulation of Src activity in response to the anti-invasive Src inhibitor dasatinib. A fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET) Src biosensor was used to monitor drug-targeting efficacy in a transgenic p53-mutant mouse model of pancreatic cancer. In contrast to conventional techniques, FLIM-FRET analysis allowed for accurate, time-dependent, live monitoring of drug efficacy and clearance in live tumors. In 3D organotypic cultures, we showed that a spatially distinct gradient of Src activity exists within invading tumor cells, governed by the depth of penetration into complex matrices. In parallel, this gradient was also found to exist within live tumors, where Src activity is enhanced at the invasive border relative to the tumor cortex. Upon treatment with dasatinib, we observed a switch in activity at the invasive borders, correlating with impaired metastatic capacity in vivo. Src regulation was governed by the proximity of cells to the host vasculature, as cells distal to the vasculature were regulated differentially in response to drug treatment compared with cells proximal to the vasculature. Overall, our results in live tumors revealed that a threshold of drug penetrance exists in vivo and that this can be used to map areas of poor drug-targeting efficiency within specific tumor microenvironments. We propose that using FLIM-FRET in this capacity could provide a useful preclinical tool in animal models before clinical translation.
Author	Sansom, Owen J Evans, T R Jeffry Nobis, Max Campbell, Andrew D Wang, Yingxiao Brunton, Valerie G McGhee, Ewan J Quinn, Jean Schwarz, Juliane P Carragher, Neil O Morton, Jennifer P Anderson, Kurt I Karim, Saadia A McGarry, Lynn C Frame, Margaret C Timpson, Paul Edward, Mike
Author_xml	– sequence: 1 givenname: Max surname: Nobis fullname: Nobis, Max organization: The Beatson Institute for Cancer Research, Glasgow; Section of Dermatology, School of Medicine, University of Glasgow, Glasgow, UK – sequence: 2 givenname: Ewan J surname: McGhee fullname: McGhee, Ewan J – sequence: 3 givenname: Jennifer P surname: Morton fullname: Morton, Jennifer P – sequence: 4 givenname: Juliane P surname: Schwarz fullname: Schwarz, Juliane P – sequence: 5 givenname: Saadia A surname: Karim fullname: Karim, Saadia A – sequence: 6 givenname: Jean surname: Quinn fullname: Quinn, Jean – sequence: 7 givenname: Mike surname: Edward fullname: Edward, Mike – sequence: 8 givenname: Andrew D surname: Campbell fullname: Campbell, Andrew D – sequence: 9 givenname: Lynn C surname: McGarry fullname: McGarry, Lynn C – sequence: 10 givenname: T R Jeffry surname: Evans fullname: Evans, T R Jeffry – sequence: 11 givenname: Valerie G surname: Brunton fullname: Brunton, Valerie G – sequence: 12 givenname: Margaret C surname: Frame fullname: Frame, Margaret C – sequence: 13 givenname: Neil O surname: Carragher fullname: Carragher, Neil O – sequence: 14 givenname: Yingxiao surname: Wang fullname: Wang, Yingxiao – sequence: 15 givenname: Owen J surname: Sansom fullname: Sansom, Owen J – sequence: 16 givenname: Paul surname: Timpson fullname: Timpson, Paul – sequence: 17 givenname: Kurt I surname: Anderson fullname: Anderson, Kurt I
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23749641$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLAzEUhYNU7EN_gpKlm9RkkjSZZSmtFqqC1PWQ15TINDMmMwX_fQNWcHUP937nwLlTMAptcADcEzwnhMsnjLFEnIlivlq-IVIgxhm_AhPCqUSCMT76p8dgmtJXtnCC-Q0YF1SwcsHIBOht6KM6-V41cLPbvqLNx3oP_VEdfDjA6E5ONQlalVTvg9fIBzsYZ2Hq8iJ7TJv9bQPbGqZooA-wU8FEl68GmixdvAXXdQ5xd5c5A5-b9X71gnbvz9vVcocMw7xHphAl1a6WnMnamFpbWxYUm5IaSSTnmmkriLOMO0EpFrUgWktLGF0ooaktZuDxN7eL7ffgUl8dfTKuaVRw7ZCqTHLJFpiUGX24oIM-Olt1MTeOP9XfX4ozdy5n8A
CitedBy_id	crossref_primary_10_1016_j_devcel_2015_11_026 crossref_primary_10_1038_s41568_023_00610_5 crossref_primary_10_1016_j_addr_2014_10_015 crossref_primary_10_1016_j_addr_2023_115081 crossref_primary_10_1038_nchembio_2096 crossref_primary_10_1038_srep32412 crossref_primary_10_1039_C5AN01861G crossref_primary_10_1093_carcin_bgu108 crossref_primary_10_1007_s10495_018_1459_6 crossref_primary_10_1038_s41581_021_00481_9 crossref_primary_10_1002_biot_201300198 crossref_primary_10_4155_tde_14_44 crossref_primary_10_1016_j_ceb_2021_04_007 crossref_primary_10_3389_fphy_2020_576862 crossref_primary_10_1002_biot_201300196 crossref_primary_10_1016_j_pharmthera_2019_107429 crossref_primary_10_1016_j_ydbio_2017_04_015 crossref_primary_10_3390_ijms22010148 crossref_primary_10_1038_s41388_023_02701_x crossref_primary_10_1242_jcs_206995 crossref_primary_10_3390_life12040516 crossref_primary_10_1038_onc_2014_28 crossref_primary_10_1042_BST20220162 crossref_primary_10_1016_j_ymeth_2017_04_014 crossref_primary_10_1242_jcs_234922 crossref_primary_10_1016_j_chembiol_2013_12_012 crossref_primary_10_1016_j_canlet_2015_11_048 crossref_primary_10_1109_TBME_2015_2491364 crossref_primary_10_37188_lam_2025_049 crossref_primary_10_1002_cbic_201402061 crossref_primary_10_1038_onc_2017_63 crossref_primary_10_1088_2050_6120_acc0d9 crossref_primary_10_1038_mi_2016_65 crossref_primary_10_1186_s13058_015_0592_1 crossref_primary_10_3389_fpls_2018_00639 crossref_primary_10_1016_j_bios_2016_04_050 crossref_primary_10_1074_jbc_REV119_006177 crossref_primary_10_1038_nrc3742 crossref_primary_10_1146_annurev_pharmtox_010617_053137 crossref_primary_10_1038_ncomms10664 crossref_primary_10_1136_gutjnl_2018_316822 crossref_primary_10_4155_fmc_2016_0025 crossref_primary_10_1080_21541248_2018_1438024 crossref_primary_10_1371_journal_pone_0144421 crossref_primary_10_1016_j_biotechadv_2024_108466 crossref_primary_10_1111_cas_13132 crossref_primary_10_12688_f1000research_8090_1 crossref_primary_10_1002_adfm_201910369 crossref_primary_10_4155_tde_13_93 crossref_primary_10_1080_21541248_2017_1345712 crossref_primary_10_3389_fbioe_2020_595497 crossref_primary_10_1016_j_bbalip_2013_09_012 crossref_primary_10_1016_j_yexcr_2024_114166 crossref_primary_10_7554_eLife_35800 crossref_primary_10_1002_adhm_201701148 crossref_primary_10_1016_j_semcancer_2015_08_007 crossref_primary_10_1038_nprot_2016_121 crossref_primary_10_1038_s41598_017_17177_5 crossref_primary_10_1016_j_jconrel_2018_07_032 crossref_primary_10_1038_nrc_2017_41 crossref_primary_10_1038_onc_2017_362 crossref_primary_10_1111_pin_12925 crossref_primary_10_1038_nrd_2016_175 crossref_primary_10_1042_EBC20190012 crossref_primary_10_1016_j_addr_2016_05_023 crossref_primary_10_3390_cells13131114 crossref_primary_10_1016_j_ejmech_2014_10_003 crossref_primary_10_3390_s151026281 crossref_primary_10_1038_onc_2016_522 crossref_primary_10_1093_nar_gkad030 crossref_primary_10_3390_photonics2041027 crossref_primary_10_1038_nrc3724 crossref_primary_10_1158_0008_5472_CAN_15_3534 crossref_primary_10_1038_s43586_022_00168_w crossref_primary_10_1111_febs_15011
ContentType	Journal Article
Copyright	2013 AACR.
Copyright_xml	– notice: 2013 AACR.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/0008-5472.CAN-12-4545
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-7445
ExternalDocumentID	23749641
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: Cancer Research UK grantid: 12481 – fundername: Cancer Research UK grantid: 11650 – fundername: Cancer Research UK grantid: 15565 – fundername: NHLBI NIH HHS grantid: HL109142 – fundername: Cancer Research UK grantid: 15703 – fundername: NHLBI NIH HHS grantid: HL098472 – fundername: NHLBI NIH HHS grantid: K02 HL109142
GroupedDBID	--- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 UDS W2D W8F WH7 WOQ YKV YZZ 7X8
ID	FETCH-LOGICAL-c405t-c2793bef8548fccfbdd9230c93c81855b4bd71ed45e73307f71bb8d1436a7b3d2
IEDL.DBID	7X8
ISICitedReferencesCount	96
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000322620800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1538-7445
IngestDate	Thu Sep 04 19:41:23 EDT 2025 Mon Jul 21 06:05:06 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	15
Language	English
License	2013 AACR.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c405t-c2793bef8548fccfbdd9230c93c81855b4bd71ed45e73307f71bb8d1436a7b3d2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	23749641
PQID	1435846019
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1435846019 pubmed_primary_23749641
PublicationCentury	2000
PublicationDate	2013-08-01
PublicationDateYYYYMMDD	2013-08-01
PublicationDate_xml	– month: 08 year: 2013 text: 2013-08-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cancer research (Chicago, Ill.)
PublicationTitleAlternate	Cancer Res
PublicationYear	2013
SSID	ssj0005105
Score	2.4440827
Snippet	Cancer invasion and metastasis occur in a complex three-dimensional (3D) environment, with reciprocal feedback from the surrounding host tissue and...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	4674
SubjectTerms	Animals Antineoplastic Agents - pharmacology Biosensing Techniques - methods Cells, Cultured Dasatinib Disease Models, Animal Fluorescence Resonance Energy Transfer - methods Imaging, Three-Dimensional - methods Mice Mice, Transgenic Microscopy, Fluorescence Pancreatic Neoplasms - metabolism Pyrimidines - pharmacology src-Family Kinases - metabolism Thiazoles - pharmacology
Title	Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/23749641 https://www.proquest.com/docview/1435846019
Volume	73
WOSCitedRecordID	wos000322620800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3Ivga7SVp2ieRsaLgypApeyvNpdAH27nO_X7PaTv2JAi-9C2QpF_O-ZJ8OR8hd5wLhcSWZZHwGJcqY5kTZMwCeFSA7hZNtc-PV5kk4XQajbsDt7qTVa5iYhOoTaXxjPwB8zrkSmAkj7Mvhq5ReLvaWWhskp4PVAZRLafrauGilTA2i1pCr7oXPK4I8QFDyASX3v3gKUF5Ahdc_M4ym2wT7_-3nwdkr-OZ9KkFxiHZsOUR2Rl1N-nHRL3gqe4SLUNoDBGMxW_DCS0-G9MiinWdAJfUZCj2KQvFYOsOIDC0RgU2tOkk7rTKaT3XtCgphJWWgWqqEUrzE_IeDyeDZ9b5LTANtG3BtAeLVdk8hF1MrnWujAH65-jI15jWheLKSNcaLqz0ITbk0lUqNDDiIJPKN94p2Sqr0p4T6mSGKxs4FggEvl0FUqKEJ41UOve1p_vkdjV7KeAZLymy0lbfdbqevz45a39BOmsLb6SeL3kUcPfiD60vya7XOFegVu-K9HKYNXtNtvVyUdTzmwYo8E3Gox8igcYk
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intravital+FLIM-FRET+imaging+reveals+dasatinib-induced+spatial+control+of+src+in+pancreatic+cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Nobis%2C+Max&rft.au=McGhee%2C+Ewan+J&rft.au=Morton%2C+Jennifer+P&rft.au=Schwarz%2C+Juliane+P&rft.date=2013-08-01&rft.eissn=1538-7445&rft.volume=73&rft.issue=15&rft.spage=4674&rft_id=info:doi/10.1158%2F0008-5472.CAN-12-4545&rft_id=info%3Apmid%2F23749641&rft_id=info%3Apmid%2F23749641&rft.externalDocID=23749641
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon